Roth/MKM initiates Abeona Therapeutics stock with buy rating By Investing.com
Investing.com Canada
Roth/MKM has initiated coverage on Abeona Therapeutics (NASDAQ: ABEO) with a Buy rating and a price target of $17.00, citing the undervaluation of the stock and the strong profile of its therapy, ZEVASKYN. The firm projects Abeona Therapeutics to achieve GAAP net income profitability by Q1 2027 and over $275 million in sales by 2029, with significant revenue growth already demonstrated by ZEVASKYN. ZEVASKYN, priced at $3.1 million, targets a rare skin disease and has received no payor denials, w
Read the full story
This is a short summary. The complete article is published by Investing.com Canada.
Headline and summary aggregated from public news feeds. For information only — not financial advice.